RxDoctor Payments Data

James Wang, MD

Neurology · Memphis, TNNPI 1619945532

Payments from drug & device makers

$27,114in general payments, 2019–2025

Across 561 payments — averaging $48.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$7K
  • Pfizer$5K
  • Argenx US, Inc.$5K
  • Amneal Pharmaceuticals LLC$2K
  • AbbVie$1K
  • AstraZeneca$1K
  • plus $6K from 51 others

What the payments were for

  • Consulting fees$15,54857%
  • Speaking & faculty fees$410%
  • Travel & lodging$1,0394%
  • Food & beverage$10,27238%
  • Education$2151%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen(2 entities)42$6,908
Pfizer35$5,462
Argenx US, Inc.23$4,737
Amneal Pharmaceuticals LLC17$1,630
AbbVie(2 entities)86$1,129
AstraZeneca(2 entities)39$1,092
Novartis54$1,028
UCB, Inc.39$892
Biogen16$457
Teva Pharmaceuticals USA, Inc.22$342
SK Life Science, Inc.9$310
EMD Serono, Inc.28$305
Sunovion Pharmaceuticals Inc.17$275
Lundbeck LLC10$221
Genentech USA, Inc.13$204
TG Therapeutics, Inc.9$191
Johnson & Johnson(2 entities)8$176
Biohaven Pharmaceuticals, Inc.10$157
Neurocrine Biosciences, Inc.5$132
Banner Life Sciences, LLC6$125
Biohaven Pharmaceutical Holding Company Ltd.5$96
Eisai Inc.5$95
Supernus Pharmaceuticals, Inc.4$78
Catalyst Pharmaceuticals, Inc.4$69
Neurelis, Inc.4$69
Bristol Myers Squibb4$67
CSL Behring4$65
Takeda Pharmaceuticals U.S.A., Inc.2$57
Upsher-smith Laboratories LLC2$46
Portola Pharmaceuticals, LLC2$46
Acorda Therapeutics, Inc2$41
Acadia Pharmaceuticals Inc3$40
Galderma Laboratories, L.p.2$40
GE HealthCare2$38
E.r. Squibb & Sons, L.L.C.2$36
Akcea Therapeutics, Inc.2$32
Lilly USA, LLC2$32
Avanir Pharmaceuticals, Inc.2$32
Bayer1$31
Otsuka America Pharmaceutical, Inc.2$31
Axsome Therapeutics, Inc.1$29
Sanofi1$26
Cycle Pharmaceuticals Inc1$24
Jazz Pharmaceuticals Inc.1$23
Grifols USA, LLC1$23
MDD US Operations, LLC1$21
Livanova USA, Inc.1$18
Sumitomo Pharma America, Inc.1$15
Ultragenyx Pharmaceutical Inc.1$15
Tanabe Pharma America, Inc.1$15
Zyla Life Sciences, Inc.1$15
Arbor Pharmaceuticals, Inc.1$15
Assertio Therapeutics, Inc.1$14
Scilex Pharmaceuticals Inc.1$13
Vertical Pharmaceuticals, LLC1$12
Harmony Biosciences LLC1$12
Biosense Webster, Inc.1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$27,114 in reported general payments places this provider in the 75th percentile of 361 neurology providers in Tennessee.

See all neurology providers in Tennessee

Medicare billing

Part B allowed, 2024
$5,671,625
Medicare patients
681
Services billed
88,382

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CopaxoneGlatiramer Acetate21$122,150
RytaryCarbidopa/Levodopa29$19,142
Gabapentin625$7,310
Levetiracetam193$5,590
Carbamazepine93$4,734
Pyridostigmine Bromide29$4,485
Divalproex Sodium138$4,451
Topiramate219$3,304
AmantadineAmantadine Hcl50$3,288
Donepezil Hcl304$3,092
Amitriptyline Hcl212$2,327
Baclofen171$2,014
Carbamazepine ErCarbamazepine18$1,999
Primidone82$1,609
Memantine Hcl50$1,430

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Copaxone$342$122,15021 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide$1,630$23,62758 claims
Upsher-smith Laboratories LLCTopiramate$46$3,304219 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 361 neurology providers in Tennessee.

Other neurology in Memphis

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →